Green Cross Medical Science Corporation Asset Resilience Ratio
Green Cross Medical Science Corporation asset resilience ratio. Green Cross Medical Science Corporation (142280) has an Asset Resilience Ratio of 9.78% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 142280 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Green Cross Medical Science Corporation (2016–2023)
Asset resilience ratio of Green Cross Medical Science Corporation from 2016 to 2023. This chart shows how Green Cross Medical Science Corporation's Asset Resilience Ratio has changed over time. Read debt load of Green Cross Medical Science Corporation for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Green Cross Medical Science Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 142280 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩9.41 Billion | 9.78% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩9.41 Billion | 9.78% |
Asset Resilience Insights
- Limited Liquidity: Green Cross Medical Science Corporation maintains only 9.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Green Cross Medical Science Corporation Industry Peers by Asset Resilience Ratio
Compare Green Cross Medical Science Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Green Cross Medical Science Corporation Asset Resilience Ratio by Year (2016–2023)
Green Cross Medical Science Corporation asset resilience ratio by year from 2016 to 2023. The table below shows the annual Asset Resilience Ratio data for Green Cross Medical Science Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | ₩0.00 ≈ $0.00 |
₩90.53 Billion ≈ $61.35 Million |
-- |
| 2022-12-31 | 11.14% | ₩10.75 Billion ≈ $7.28 Million |
₩96.47 Billion ≈ $65.38 Million |
+9.22pp |
| 2021-12-31 | 1.92% | ₩1.84 Billion ≈ $1.25 Million |
₩95.63 Billion ≈ $64.81 Million |
-2.34pp |
| 2020-12-31 | 4.26% | ₩4.50 Billion ≈ $3.05 Million |
₩105.60 Billion ≈ $71.57 Million |
-11.14pp |
| 2019-12-31 | 15.40% | ₩13.68 Billion ≈ $9.27 Million |
₩88.87 Billion ≈ $60.22 Million |
+1.40pp |
| 2018-12-31 | 13.99% | ₩8.95 Billion ≈ $6.07 Million |
₩63.97 Billion ≈ $43.35 Million |
+8.04pp |
| 2017-12-31 | 5.95% | ₩3.60 Billion ≈ $2.44 Million |
₩60.54 Billion ≈ $41.03 Million |
+2.10pp |
| 2016-12-31 | 3.85% | ₩2.45 Billion ≈ $1.66 Million |
₩63.61 Billion ≈ $43.10 Million |
-- |
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more